Anasens Inc., a developer of rapid, connected point-of-care detection tools,  announced it has signed a distribution agreement with MAVAND Solutions GmbH for the commercialization of DrugAsens™, Anasens’ oral-fluid multidrug testing solution, in key countries across Europe and in Australia. The agreement strengthens Anasens’ international footprint and accelerates access to fast, reliable screening for workplaces, law enforcement, and specialized clinics.

“Partnering with MAVAND gives DrugAsens™ a trusted, on-the-ground channel to reach customers who need rapid results and simple workflows,” said Véronique Bougie, Chief Operating Officer of Anasens. “Together, we’ll expand access to rapid saliva-based drug testing for roadside law enforcement and workplace safety programs across major industries in several EU countries.”

“DrugAsens™ represents exactly the type of innovation MAVAND wants to bring to market,” said Ina Beckers, Managing Director at MAVAND Solutions GmbH. “By combining Anasens’ breakthrough technology with our established network, we are well positioned to set a new standard for oral-fluid drug testing in Europe and Australia.”

Under the agreement, MAVAND will market, sell, and support DrugAsens™ in selected EU markets and in Australia, with joint go-to-market activities, training, and post-sales support planned over the coming years.

This announcement marks an important first step for Anasens: building on this partnership, Anasens intends to accelerate its commercial expansion by rapidly entering into new distribution agreements across the world, ensuring complete and consistent market coverage.